Please assess the completion status of the following clinical trial:

Trial Title: Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients with atrial fibrillation and an indication for oral anticoagulation (CHA2DS2-VASc score≥ 1).~* Current clopidogrel treatment~* Informed, written consent by the patient or her/his legally-authorized representative for participation in the study.~Key Exclusion Criteria:~* Age ≤18 years~* Cardiogenic shock~* Current therapy with dabigatran~* Patients with a recent thromboembolic event and high thromboembolic risk requiring bridging therapy with either unfractionated heparin or LMWH~* Contraindication for oral anticoagulation~* Active bleeding~* Known allergy or intolerance to the study medications: dabigatran, phenprocoumon

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Dabigatran Therapy
- Arm 2 (Type: ACTIVE_COMPARATOR): Phenprocoumon Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).